Status:
UNKNOWN
Anti-Restenosis After AMI by Erythropoietin
Lead Sponsor:
Kyoto Prefectural University of Medicine
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
20-79 years
Phase:
PHASE4
Brief Summary
The EPOC-AMI study is to assess the safety and the efficacy of systemic administration of erythropoietin for inhibition of neointimal hyperplasia after stent implantation in the patients with acute my...
Detailed Description
Stents coated with sirolimus or paclitaxel have been shown to significantly reduce restenosis in selected coronary lesions. However, the potential risk of late stent thrombosis forces prolonged treatm...
Eligibility Criteria
Inclusion
- Clinical diagnosis of acute myocardial infarction within 12hrs of symptom onset.
- Succeeded reperfusion due to primary PCI accomplished bare metal stent
Exclusion
- Patients with cardiogenic shock (e.g. systolic BP\<80mmHg,use of catecholamine, use of IABP)
- Patients with anemia required transfusion
- Patients who are unwilling or unable to comply with the trial protocol
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00423020
Last Update
January 17 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kyoto Prefectural University of Medicine
Kyoto, Kyoto, Japan, 602-8566